Who is capmatinib suitable for?

Capmatinib (Capmatinib) is a revolutionary oral small molecule mesenchymal epithelial transition (MET) inhibitor developed by Novartis Oncology under license from Incyte Corporation, specifically for the treatment of lung cancer. In May 2020, capmatinib received the first global approval in the United States for the treatment of adults with metastatic non-small cell lung cancer (NSCLC). Its unique targeted mechanism of action allows it to show significant efficacy in the treatment of specific types of non-small cell lung cancer.

Capmatinib is mainly suitable for patients with metastatic non-small cell lung cancer whose tumors have mutations that lead to mesenchymal-epithelial transition (MET) exon 14 skipping. This mutation leads to abnormal activation of the MET protein, which in turn drives the proliferation and spread of tumor cells. Capmatinib can specifically inhibit this abnormal activation, thereby blocking tumor growth and metastasis.

In clinical practice, the efficacy of capmatinib has been widely recognized. A multi-cohort phase 2 clinical study showed that capmatinib showed good therapeutic effects in patients with advanced non-small cell lung cancer with MET exon 14 skipping mutations and MET amplification. For previously treated patients, the overall response rate was 41%, and for treatment-naïve patients, the overall response rate was as high as 68%.

However, it should be noted that capmatinib is not suitable for all patients with non-small cell lung cancer. Its applicable population is mainly limited to patients with specific genetic markers (i.e. MET exon 14 skipping mutations). Therefore, before using capmatinib, doctors will perform genetic testing on patients to determine whether this specific mutation is present.

In addition, for special groups such as pregnant women, lactating women, pediatric patients, and the elderly, capmatinib needs to be used with extreme caution. Pregnant women taking capmatinib may cause fetal harm, so it is recommended to use effective contraceptive measures during treatment and for a period of time after stopping the drug. At the same time, because capmatinib may be excreted through breast milk, lactating women should also avoid breastfeeding during treatment. In pediatric patients, the safety and efficacy of capmatinib have not been established and its use is not recommended. For elderly patients, although no differences in safety or effectiveness compared with younger patients were found in clinical trials, the patient's overall health status and comorbidities still need to be carefully evaluated.

Overall, capmatinib, as a new type of targeted therapy, provides a new treatment option for patients with non-small cell lung cancer who have specific genetic markers. However, during use, it is necessary to determine whether it is suitable and how to use it based on the patient's specific situation and the doctor's advice.